Navigation Links
Video: The MDS Foundation Says Published Data Confirms VIDAZA(R) Significantly Extends Survival in Patients with the Malignant Condition MDS
Date:2/18/2009

VIDAZA Restores Gene Function to Double Survival and Increase Transfusion Independence

CROSSWICKS, N.J., Feb. 18 /PRNewswire/ -- The Myelodysplastic Syndromes (MDS) Foundation says data published in the peer reviewed medical journal The Lancet Oncology confirms VIDAZA extends survival for patients with higher-risk MDS. Myelodysplastic syndromes are a group of blood-related malignancies that are difficult to treat and in higher-risk patients have a median survival rate of less than one year. Symptoms include anemia and fatigue, and often patients must rely on blood transfusions to manage the symptoms. VIDAZA, also known by its chemical name, azacitidine, represents a new approach to treatment with important benefits for patients with MDS, and a related condition called acute myeloid leukemia (AML).

To view the Multimedia News Release, go to: http://www.prnewswire.com/mnr/mds-foundation/37124/

"The data from this large international study of VIDAZA is important news for the patients we represent, validating a new treatment option and offering tangible results for this difficult-to-treat disease," said Kathy Heptinstall, Operating Director of the Myelodysplastic Syndromes Foundation.

"VIDAZA was able to essentially double survival at two years compared to conventional care," says Lewis Silverman, M.D., of Mount Sinai Medical Center in New York and senior study author. "VIDAZA is the first and only drug that we know extends survival."

In MDS, genes responsible for orderly growth and development of cells in the bone marrow are turned off or silenced, allowing the cells to become malignant. VIDAZA turns these genes back on through a system of actions called epigenetics, a new approach to cancer treatment. It is also the first drug to achieve transfusion independence in more than 40% of patients. Transfusions can be time consuming, debilitating and run the risk of iron overload that can be fatal.

MDS patient Bob Urbanski notes, "I needed blood transfusions as often as twice a month, but with VIDAZA I haven't needed a transfusion for at least 14 weeks."

The published data refer specifically to categories of MDS known as intermediate-2 or high-risk MDS, as well as AML with 20 to 30 percent bone marrow blasts. VIDAZA has been available in the United States for four years and it was recently approved in Europe.

About MDS

MDS is a primary neoplasm of the bone marrow that is more prevalent than any of the leukemias. MDS affects the function of blood cells; red blood cells, white blood cells or platelets. It is not known exactly how many people have MDS, however, according to current estimates, there are between 15,000 and 20,000 people diagnosed each year in Europe.

About the MDS Foundation

The Myelodysplastic Syndromes Foundation, Inc. is a multi-disciplinary, international organization devoted to the prevention, treatment, and study of the myelodysplastic syndromes. The organization is based upon the premise that international cooperation will accelerate the process leading to the control and cure of these diseases. For further information, please visit http://www.mds-foundation.org.

    Press Contact:
    Kathy Heptinstall
    Operating Director
    The MDS Foundation, Inc.
    1-800-MDS-0839


'/>"/>
SOURCE The Myelodysplastic Syndromes Foundation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Video: Nutrition Comes to NASCAR
2. Video: Circulatory Care of New Jersey
3. Video: GEN Video Hits Home with Web Audience
4. Video: Beyond the Red Door: Gildas Club Worldwide and DKNY Host Successful Benefit Event
5. Video: Food Expert B. Smith to Provide Healthy Menu Makeovers
6. Video: New FDA-Approved Sun Protectant Saves Skin All Year Round
7. Video: Kyphon Supports World Osteoporosis Day on October 20, 2007 to Raise Awareness of Osteoporosis and Spinal Fracture Risk
8. Video: Trinity Mother Frances Neurosurgeon First in Region to Remove Brain Tumor Using Unique Surgical Procedure
9. Video: Holiday Safety Is Important
10. Video: Grin Big With an Award-Winning Smile
11. Video: BSP Pharma Inc. Announces Groundbreaking Findings from The Australian Centre for Complementary Medicine Education and Research Joint Health Clinical Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... 27, 2016 , ... More than a third of American adults are considered ... surgery has received increased attention in recent years, as an article published ... weight loss, most people are familiar with the basic requirements of maintaining a healthy ...
(Date:5/27/2016)... ... ... With over 60 percent of acute stroke survivors being left unable to ... in the rehabilitation process has steadily increased. Ekso Bionics had been working to help ... stroke. , Ekso Bionics has now received clearance from the U.S. Food and Drug ...
(Date:5/27/2016)... ... May 27, 2016 , ... Aimed ... by inspiring human interest stories, courtesy of leaders in the nursing and health ... the industry, from leading advocates and associations—namely Jones & Bartlett Learning. , Jones ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research commissioned ... dogs straight off the grill. Of the 90 percent of Americans who say they ... hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving (9 ...
(Date:5/26/2016)... , ... May 26, 2016 , ... Connor Sports, ... basketball as a partner for the Tamika Catchings Legacy Tour that will ... industry leader in hardwood basketball surfaces in all forms and levels of the game, ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... MedDay, a biotechnology company focused on the treatment ... "High doses of biotin in progressive multiple sclerosis: extension phase ... Ayman Tourbah , Principal Investigator of the Phase 3 ... Neurology (EAN) in Copenhagen, Denmark . The ... on Sunday, 29 May 2016 from 14:45 to 16:15 CEST ...
(Date:5/24/2016)... --   , ... Endpunkte und demonstriert Ebenbürtigkeit bei der Gesamtreinigung des ... guter , Reinigung des ... (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ) , ... der MORA-Studie der Phase III für NER1006 (1 ...
(Date:5/24/2016)... Celsion Corporation (NASDAQ: CLSN ... an update on its ongoing OVATION study, a ... the Company,s DNA-based immunotherapy, with the standard of ... advanced ovarian cancer who will undergo neoadjuvant chemotherapy ... IL-12 DNA plasmid vector formulated as a nanoparticle ...
Breaking Medicine Technology: